The Incidence of Invasive Aspergillosis in Acute Myeloid Leukemia
The study conducted by University Hospital, Brest, addresses the significant morbidity and mortality associated with invasive aspergillosis (IA) in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy. The findings could influence antifungal prophylaxis practices, particularly the use of posaconazole, which may enhance patient outcomes and reduce healthcare costs associated with IA. Given the high incidence of IA in this patient population, the market for antifungal agents, particularly those targeting IA, remains robust. The competitive landscape includes established antifungals like voriconazole and newer agents, which may pose challenges for posaconazole's market share. Diligence should focus on the efficacy data and potential shifts in treatment guidelines based on this study's outcomes.
Indication: Acute Myeloid Leukemia
Modality: protein therapy
Target: Invasive Aspergillus species
Sponsor: University Hospital, Brest
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Invasive Aspergillus species
View original source fields
Condition raw: Acute Myeloid Leukemia, Invasive Aspergillosis
Condition normalized: Acute Myeloid Leukemia, Invasive Aspergillosis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Invasive Aspergillus species
Target normalized: Invasive Aspergillus species